The year started strong for Jazz Pharmaceuticals (JAZZ) with a Q4 2024 revenue beat and the company guiding 2025 revenues just slightly below the analyst consensus. However, the stock is down 22% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback